Zurich Cantonal Bank
DYN icon

Zurich Cantonal Bank’s Dyne Therapeutics DYN Stock Holding History

Zurich Cantonal Bank’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-37,307
Closed -$730K – 2861
2025
Q4 		$730K Buy
+37,307
New +$706K ﹤0.01% 1543

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Orbis Allan Gray
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Zurich Cantonal Bank's DYN Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Dyne Therapeutics (DYN) stake by 13% in Q2 2026, buying an estimated $126K and bringing the position to 58,947 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1381.

Zurich Cantonal Bank first reported a position in DYN in Q2 2023 and has held it in 12 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Zurich Cantonal Bank held 58,947 shares of Dyne Therapeutics worth $1.31M as of Q2 2026.
  • Zurich Cantonal Bank bought 6,795 Dyne Therapeutics shares in Q2 2026, an estimated $126K.
  • Dyne Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1381 holding.
  • Zurich Cantonal Bank first reported a position in Dyne Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.